Piracetam
Piracetam is a cyclic derivative of GABA (2-oxo-1-pyrrolidine acetamide) marketed as a "nootropic." It is the parent of the racetam class and is used in some countries as a prescription drug for cortical myoclonus and, controversially, for age-related cognitive decline; it is not FDA-approved and is sold in the US only as an unregulated research chemical/supplement. The best human evidence is for cortical myoclonus (notably Unverricht-Lundborg disease), where randomized trials show real, dose-dependent benefit at very high doses (up to ~24 g/day and more). For the reason most people take it (cognitive enhancement in healthy adults), there is essentially no adequate human RCT evidence, and the dementia literature is weak and conflicting (a Cochrane review concluded the evidence does not support its use). Risks are modest at typical doses but real: a large acute-stroke RCT (PASS) found no benefit and a non-significant trend toward higher mortality; piracetam is renally cleared unchanged, so it accumulates in kidney impairment; it has hemorheologic/antiplatelet activity that raises theoretical bleeding risk, especially with anticoagulants; and it commonly causes CNS activation (agitation, insomnia, irritability, hyperkinesia). It crosses the placenta. This is not a performance/physique drug and carries no legitimate "stack to get bigger/leaner" use.
Mechanism of action
Pharmacokinetics
Commonly reported plasma elimination half-life is approximately 4-5 hours in adults (longer in CSF and prolonged in renal impairment); a primary human study during labor documented rapid elimination with roughly 50% cleared within ~80 minutes after IV dosing. Precise half-life data in healthy resting adults were not independently reverified here beyond the commonly cited value.
Short; typically dosed 2-3 times daily in clinical trials to maintain levels. Steady state reached within ~1-2 days.
Oral (near-complete bioavailability) and intravenous; both used in randomized trials (e.g., IV 12 g bolus in the acute-stroke trial, oral divided dosing in myoclonus trials).
Essentially not metabolized; excreted largely unchanged by the kidneys. Clearance is renal and creatinine-clearance-dependent, so it accumulates in renal impairment and requires dose reduction or avoidance. Crosses the placenta and the blood-brain barrier. This information is provided for monitoring and washout planning, not to evade any test.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Dose-dependent reduction of cortical myoclonus severity, motor impairment and functional disability in progressive myoclonus epilepsy (Unverricht-Lundborg disease), demonstrated in randomized trials at 9.6-24 g/day
- No proven benefit on functional outcome in acute ischemic stroke when given within 12 hours (large RCT)
- Weak/conflicting evidence in dementia and age-related cognitive impairment: pooled data show an effect only on a global clinical impression of change, with no consistent benefit on specific cognitive measures
- No adequate human RCT evidence for cognitive enhancement in healthy adults: the most common real-world use is unsupported by primary human data
- Not effective for cognitive symptoms of Lewy body dementia in meta-analysis
Adverse effects by system
No established direct cardiotoxicity. In the PASS acute-stroke RCT, 12-week mortality was numerically higher with piracetam than placebo (23.9% vs 19.2%, relative risk 1.24, 95% CI 0.97-1.59, not statistically significant); causation was not established, but this is a safety signal in a sick population.
No hepatotoxicity signal reported. Piracetam is not hepatically metabolized and is excreted essentially unchanged by the kidneys, making clinically meaningful liver injury unlikely; no primary human hepatotoxicity data were identified.
No adequate human data. Piracetam is non-hormonal and there is no evidence it suppresses the hypothalamic-pituitary-gonadal axis; it is not a SERM, AAS, or hormonal agent.
Piracetam crosses the placenta and appears in fetal blood/urine and amniotic fluid (human data during labor); it is generally avoided in pregnancy and lactation. No human fertility or sex-hormone effect data were identified.
Most frequently reported class of adverse effects. CNS activation (nervousness, agitation, irritability, anxiety, insomnia and, in some patients, hyperkinesia) is described; depression and somnolence have also been reported. In controlled myoclonus trials adverse effects were characterized as few, mild and transient.
The kidney is the primary elimination route (unchanged drug). Renal impairment causes accumulation, so reduced clearance is the main renal concern; direct nephrotoxicity is not established.
Piracetam has antiplatelet/hemorheologic activity (reduced platelet aggregation, increased red-cell deformability), the basis for its historical vascular and sickle-cell use. This implies a theoretical increased bleeding risk, particularly combined with anticoagulants/antiplatelets, though direct controlled human bleeding-outcome data are limited.
No consistent dermatologic adverse effect identified in the primary literature reviewed; angioedema and rash appear in post-marketing labeling but were not verified against a primary human source here.
HPTA suppression & recovery
Suppression: None expected / no adequate human data
Piracetam is non-hormonal and is not known to suppress the HPTA; there is no established role for a SERM or any post-cycle/recovery protocol with this compound. Anyone with actual HPTA or fertility concerns, or considering any SERM, should consult an endocrinologist rather than self-managing.
Monitoring
Cadence: Baseline before use; recheck renal function periodically and any time kidney function may change (illness, dehydration, new nephrotoxic drugs); reassess promptly if new psychiatric, bleeding, or neurologic symptoms appear.
- Unusual bleeding or bruising, GI bleeding, or prolonged bleeding
- Marked agitation, insomnia, irritability, anxiety, or hyperkinesia/involuntary movements
- Signs of worsening kidney function (reduced urine output, edema)
- New or worsening depression or mood change
Contraindications
- Severe renal impairment or end-stage renal disease (renally cleared unchanged; accumulates)
- Hypersensitivity to piracetam or other pyrrolidone derivatives
- Cerebral/active hemorrhage or high bleeding risk, and concurrent anticoagulant/antiplatelet therapy (hemorheologic/antiplatelet activity; manufacturer labeling lists cerebral haemorrhage)
- Huntington's chorea (per manufacturer labeling)
- Pregnancy and breastfeeding (crosses the placenta into fetal circulation)
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Understand the evidence gap: robust human RCT support exists only for cortical myoclonus; there is no adequate human trial evidence that piracetam enhances cognition in healthy adults, and dementia data are weak and conflicting.
- Because piracetam is cleared unchanged by the kidneys, do not use it with significant renal impairment without medical supervision, and stay hydrated; get baseline and periodic kidney-function labs.
- Its antiplatelet/hemorheologic activity means combining it with anticoagulants, antiplatelets (including aspirin/NSAIDs), or other bleeding-risk drugs can raise bleeding risk; involve a clinician before combining.
- Stop and seek medical care for unusual bleeding or bruising, severe agitation/insomnia, involuntary movements, or any neurologic change.
- Avoid in pregnancy and breastfeeding; it crosses the placenta.
- Product sold outside prescription channels is unregulated and may be mislabeled or contaminated; this monograph does not endorse sourcing it.
- This is educational harm-reduction information, not medical advice or a recommendation to use, and it is not a dosing optimization guide; decisions about use, dose, and monitoring belong with a qualified clinician.
Citations (8)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Piracetam produces significant, dose-dependent improvement in cortical myoclonus (motor impairment, functional disability, global assessment) in Unverricht-Lundborg disease at oral doses of 9.6-24 g/day, and was well tolerated with few, mild, transient adverse effects.
- 02
In acute ischemic stroke, piracetam (IV 12 g bolus then 12 g/day) did not improve neurologic outcome at 4 weeks; 12-week mortality was numerically higher with piracetam (23.9% vs 19.2%, RR 1.24, 95% CI 0.97-1.59, p=0.15).
- 03
A Cochrane systematic review concluded that available published evidence does not support the use of piracetam for dementia or cognitive impairment; a significant effect was seen only on global impression of change, not on specific cognitive measures.
Meta-analysisDOI 10.1002/14651858.CD001011 ↗
- 04
An industry-authored meta-analysis of 19 double-blind placebo-controlled studies reported a favorable odds ratio for global clinical improvement with piracetam in elderly cognitive impairment/dementia.
Meta-analysisPMID 12006732 ↗
- 05
Piracetam is used for cortical myoclonus at doses ranging from 7-24 g/day and up to ~45 g/day, with good long-term tolerability and only occasional, mild, transient side effects.
- 06
In a multiple-treatments meta-analysis, symptomatic pharmacotherapy for vascular dementia (a class that includes piracetam among others) showed benefit on cognitive dysfunction, particularly in younger vascular-dementia patients.
Meta-analysisDOI 10.1007/s00213-018-4867-y ↗
- 07
Piracetam did not appear effective for cognitive/psychiatric symptoms of Lewy body dementia in a systematic review and meta-analysis.
Meta-analysisDOI 10.1176/appi.ajp.2015.14121582 ↗
- 08
Piracetam is rapidly eliminated (roughly half cleared within ~80 minutes after IV dosing during labor) and crosses the placenta, appearing in fetal blood/urine and amniotic fluid.
CohortPMID 700571 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice